Xagena Medicina

Cardiology Newsletter


Cardiology - CardiologyOnline.net Radial access reduces net adverse events. Two separate clinical trials were presented as a part of ACC.15, and looked at strategies to reduce major bleeding ...Cardiology Newsletter, Newsletter Cardiology, Xagena Medical News, Arrhythmia Newsletter,Drugs in Cardiology Newsletter, Cardiovascular Drugs Newsletter,  STEMI Newsletter,NSTEMI Newsletter, PCI Newsletter, UTIC Newsletter   CordaroneAtrial fibrillation: Betapace less effient than Cordarone for ...Direct factor Xa inhibitorsDirect factor Xa inhibitors: Edoxaban compared with ...Non-valvular atrial fibrillation ...Non-valvular atrial fibrillation: Dabigatran, a safe and ...ENGAGE AF-TIMI 48 trial ...ENGAGE AF-TIMI 48 trial: transition of patients from ...Antiarrhythmic drugsAntiarrhythmic drugs: Dronedarone associated with ...BivalirudinMyocardial infarction: Heparin rather than Bivalirudin after ...Dual antiplatelet therapyPRODIGY study: appropriate duration of dual antiplatelet ...Post-infarction patients: Insulin ...Post-infarction patients: Insulin resistance predicts the risk for ...DiureticsThiazide-type diuretics remain the drugs of choice for initial ...AngiomaxAngiomax alone reduces a significant number of major ...Altri risultati in cardiologyonline.net »